Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 3, 2013, Pages 346-354

  Cotte, Laurent ^a   Dellamonica, Pierre ^b   Raffi, Francois ^c   Yazdanpanah, Yazdan ^d   Molina, Jean Michel ^e   Boué, François ^f   Urata, Yasuo ^g   Chan, H Phyllis ^h   Zhu, Li ^h   Chang, Ih ^h   Bertz, Richard ^h   Hanna, George J ^h   Grasela, Dennis M ^h   Hwang, Carey ^h  

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d CENTRE HOSPITALIER DE TOURCOING   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f HÔPITAL ANTOINE BÉCLÈRE   (France)

^g National Institute of Infectious Diseases   (Japan)

^h BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antiviral activity; BMS 986001; HIV type 1; Nucleoside reverse transcriptase inhibitor; Pharmacokinetics; Safety

Indexed keywords

BMS 986001; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD CHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LABORATORY TEST; LYMPHADENOPATHY; MALE; MONOTHERAPY; NAUSEA; NIGHTMARE; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRESBYOPIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINALYSIS;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PLACEBOS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; THYMIDINE; VIRAL LOAD; YOUNG ADULT;

EID: 84880239846     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182965d12     Document Type: Article

References (18)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents: 2012 Update. Washington, DC: U.S. Department of Health and Human Services; 2012. Available at: http://aidsinfo.nih.gov/contentfiles/lv-guidelines/ adultandadolescentgl.pdf. Accessed June 1, 2013.
2. European AIDS Clinical Society. Guidelines Version 6. Paris, France: EACS; October 2011. Available at: http://www.europeanaidsclinicalsociety. org/images/stories/EACS-Pdf/EACSGuidelines-v6.0-English.pdf. Accessed June 1, 2013.
3. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach 2010 Revision. 2010. Available at: http://whqlibdoc.who.int/publication-s/2010/ 9789241599764-eng.pdf. Accessed June 1, 2013.
4. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abaca-vir. Clin Ther. 2001;23:1603-1614.
5. Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13:453-468.
6. Patel P, Bush T, Overton T, et al. Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction. Antivir Ther. 2012;17:755-761.
7. Bedimo R, Maalouf NM, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825-831.
8. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26:867-875.
9. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-299.
10. Dutschman GE, Grill SP, Gullen EA, et al. Novel 4'-substituted stavu-dine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob Agents Chemother. 2004;48: 1640-1646.
11. Yang G, Dutschman GE, Wang CJ, et al. Highly selective action of triphosphate metabolite of 4'-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT. Antiviral Res. 2007;73:185-191.
12. Yang G, Paintsil E, Dutschman GE, et al. Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile. Antimicrob Agents Chemother. 2009;53:4640-4646.
13. Li Z, Terry B, Olds W, et al. The in vitro cross-resistance profile of the NRTI BMS-986001 against known NRTI resistance mutations. Presented at: International Workshop on HIV & Hepatitis Virus Drug Resistance; June 5-9, 2012; Spain.
14. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9:65-71.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
16. Gough K, Hutchison M, Keene O, et al. Assessment of dose proportionality: report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party. Drug Inf J. 1995;29: 1039-1048.
17. Wang X, Tanaka H, Baba M, et al. Retention of metabolites of 2', 3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel anti-human immunodeficiency virus type 1 thymidine analog, in cells. Antimicrob Agents Chemother. 2009;53:3317-3324.
18. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir diso-proxil fumarate in human immunodeficiency virus-infected adults. Anti-microb Agents Chemother. 2001;45:2733-2739.